Quantcast

Pradaxa Lawsuits Move Ahead As Bernstein Liebhard LLP Notes Upcoming Status Conference in Federal Pradaxa Litigation

June 2, 2013

The firm is currently investigating Pradaxa lawsuits on behalf of individuals who allegedly suffered life-threatening episodes of Pradaxa bleeding.

New York, New York (PRWEB) June 01, 2013

The federal litigation for Pradaxa lawsuit claims continues to move ahead in U.S. District Court, Southern District of Illinois. According to court records, the next Status Conference in the Pradaxa litigation has been scheduled for June 10, 2013. The Court´s website indicates that 889 Pradaxa bleeding claims are now pending in the proceeding. (In Re: Pradaxa (Dabigatran Etexilate) Products Liability Litigation — MDL No. 2385)

“We receive Pradaxa lawsuit inquiries on a regular basis from individuals who have allegedly suffered serious episodes of internal bleeding while using this medication. We are pleased to see the Pradaxa litigation moving forward,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is currently offering free legal evaluations to alleged victims of Pradaxa bleeding.

Pradaxa Lawsuits

Pradaxa, a blood thinner used to prevent strokes in people with atrial fibrillation, was approved for U.S. sale in October 2010, and touted as an improvement over decades-old warfarin. However, according to a December 2012 report from Bloombeg.com, regulators in several countries have issued Pradaxa safety alerts since the drug was brought on the market, most of which concerned episodes of serious internal bleeding for which there is not a readily available antidote.* According to a QuarterWatch Report released by Institute for Safe Medicine Practices (ISMP) in January 2013, an analysis of hemorrhage cases reported to the U.S. Food & Drug Administration during the second quarter of 2012 found that Pradaxa bleeding is 5 times more likely to result in death compared to warfarin bleeding.** On May 1st, the Journal of Neurosurgery published a study that showed head trauma victims were more likely to die from brain bleeding if they had been using Pradaxa compared to those taking warfarin, something the study authors attributed to a lack of an antidote.***

According to court filings, all of the Pradaxa lawsuits pending in the Southern District of Illinois allege that Boehringer Ingelheim failed to adequately warn about the lack of an antidote for Pradaxa bleeding. The first trial in the litigation is scheduled to start in September 2014.

Alleged Pradaxa bleeding victims may be eligible to collect compensation for their medical bills, lost wages, pain and suffering and more. Additional information regarding Pradaxa lawsuits is available at Bernstein Liebhard LLP´s website. To arrange for a free legal consultation, please call 800-511-5092.

*bloomberg.com/news/2012-12-11/boehringer-sued-by-hundreds-over-bleeding-tied-to-pradaxa.html

**ismp.org/quarterwatch/pdfs/2012Q2.pdf

**thejns.org/doi/pdf/10.3171/2013.3.JNS12503

About Bernstein Liebhard LLP

Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs´ Hot List,” recognizing the top plaintiffs´ firms in the country, for the past 10 consecutive years.

Bernstein Liebhard LLP

10 East 40th Street

New York, New York 10016

800-511-5092

ATTORNEY ADVERTISING. © 2013 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:

Felecia L. Stern, Esq.

Bernstein Liebhard LLP

info (at) consumerinjurylawyers (dot) com

http://www.consumerinjurylawyers.com

For the original version on PRWeb visit: http://www.prweb.com/releases/prwebpradaxa-lawsuit/pradaxa-bleeding/prweb10791718.htm


Source: prweb



comments powered by Disqus